AstraZeneca (NYSE:AZN – Get Free Report) and Journey Medical (NASDAQ:DERM – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.
Risk & Volatility
AstraZeneca has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500.
Institutional and Insider Ownership
20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 7.2% of Journey Medical shares are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AstraZeneca and Journey Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AstraZeneca | 17.68% | 31.85% | 13.62% |
| Journey Medical | -7.34% | -16.07% | -5.26% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for AstraZeneca and Journey Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AstraZeneca | 0 | 3 | 16 | 0 | 2.84 |
| Journey Medical | 2 | 0 | 2 | 0 | 2.00 |
AstraZeneca currently has a consensus target price of $206.67, indicating a potential upside of 17.85%. Journey Medical has a consensus target price of $13.00, indicating a potential upside of 301.85%. Given Journey Medical’s higher probable upside, analysts clearly believe Journey Medical is more favorable than AstraZeneca.
Earnings and Valuation
This table compares AstraZeneca and Journey Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AstraZeneca | $58.74 billion | 4.63 | $10.22 billion | $7.07 | 24.80 |
| Journey Medical | $61.86 million | 1.48 | -$11.43 million | ($0.18) | -17.97 |
AstraZeneca has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.
Summary
AstraZeneca beats Journey Medical on 11 of the 14 factors compared between the two stocks.
About AstraZeneca
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
About Journey Medical
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
